Cadrenal Therapeutics Inc

Cadrenal Therapeutics Inc operates with a capital structure that is entirely equity-funded, as evidenced by a debt-to-equity ratio of 0.0 and a current ratio of 3.72, indicating strong short-term liquidity. The company has no long-term debt and maintains a market price of $5.27 per share, with a market capitalization of $15.12 million. The price-to-book ratio of 3.79 suggests that the company is trading at a premium to its book value, which may reflect investor optimism about its future growth potential. Profitability metrics for Cadrenal Therapeutics Inc are currently negative, with a return on equity of -59.94% and a return on assets of -43.85%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The operating and net losses of $2.47 million and $2.39 million, respectively, further underscore the company's current unprofitability. These performance indicators are below the typical thresholds for a profitable biotechnology firm, suggesting that the company is in an early-stage development phase. The company's revenue is not disclosed in the provided data, and there are no segment or geographic breakdowns available. This lack of detailed revenue information limits the ability to assess the company's exposure to different markets or product lines. However, the company's focus on rare endocrine disorders suggests a niche market strategy, which may involve high development costs and limited patient populations. Looking ahead, the company is expected to continue its development efforts, with no immediate revenue growth anticipated. The absence of positive operating cash flow and the presence of negative free cash flow of $2.39 million indicate that the company is not yet generating sufficient cash to fund its operations. The outlook for the next fiscal year remains uncertain, with the company likely to remain in a development and clinical trial phase. Risk factors for Cadrenal Therapeutics Inc include the inherent risks associated with biotechnology development, such as clinical trial failures, regulatory hurdles, and competition. The company's liquidity risk is currently low, as it has no immediate filing-based liquidity flags. However, the company's reliance on equity financing and the absence of long-term debt could change if it needs to raise additional capital for clinical trials or other operational needs. The dilution risk is also currently low, with no immediate filing-based dilution flags detected. Recent events for Cadrenal Therapeutics Inc include the continued development of CVD-101, with no significant filings or transcripts reported in the provided data. The company's mean price target of $27.67 and median price target of $25.00 suggest that analysts have a positive outlook on the company's future performance, despite its current unprofitability. The absence of strong-buy recommendations and the presence of two buy recommendations indicate a cautious but optimistic sentiment among analysts.